

No	Reference Number	IRAS No	Title	Target number of patients agreed?	Target range minimum	Target range maximum	Target date to recruit patients agreed?	Planned Recruitment End date	Total no of patients recruited at the agreed target date	Date study actually closed to recruitment at STH	Total no of patients recruited (current accrual)	Reason for closure of trial
1	14/NE/1129	157608	Pressure controlled Intermittent Coronary Sinus Occlusion as an adjunct to PCI in acute coronary syndrome. An observational study evaluating the effect of PICSO treatment concomitant to pPCI in patients with anterior non ST-segment Elevation Myocardial Infarction or following pPCI in ST-segment Elevation Myocardial Infarction.	Range Agreed	12	22	Date Agreed	30/06/2017	16	30/06/2017	16	Recruitment finished
2	14/LO/2182	143226	STOP-HCC TS-103 A phase 3 clinical trial of intra-arterial TheraSphere in the treatment of patients with unresectable hepatocellular carcinoma	Number Agreed	2	2	Date Agreed	15/01/2018	6	04/09/2017	6	Recruitment finished
3	14/YH/1141	161305	A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy	Number Agreed	2	2	Date Agreed	15/03/2018	2	30/11/2017	2	Withdrawn By Sponsor
4	14/SS/1087	164169	A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC4061, 30mg to 120mg/day, split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease	Number Agreed	1	1	Date Agreed	31/05/2017	1	28/02/2017	1	Recruitment Finished
5	15/YH/0287	174975	An open-label study of Dupilumab in patients with atopic dermatitis who participated in previous Dupilumab clinical trials.	Number Agreed	5	5	Date Agreed	28/02/2017	10	28/02/2017	10	Recruitment Finished

6	15/WM/0327	185434	Clinical evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS) system for pulmonary artery denervation in patients with pulmonary hypertension. (TROPHY)	Range Agreed	1	5	Date Agreed	30/09/2017	6	14/09/2017	6	Recruitment finished
7	15/LO/1670	188788	Randomised, placebo-controlled, double-blind Phase 2 study of Patritumab (U3-1287) in combination with Cetuximab plus platinum-based therapy in first line setting in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck.	Range Agreed	1	12	Date Agreed	21/07/2017	3	21/06/2017	3	Recruitment Finished
8	15/EM/0443	187983	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	Number Agreed	7	7	Date Agreed	30/03/2017	7	30/03/2017	7	Recruitment Finished
9	16/NE/0028	188506	SOLAR Study - An open-label, randomised Phase 3 efficacy study of ASP8273 vs Erlotinib or Gefitinib in first-line treatment of patients with Stage IIIB/IV Non-small Cell Lung Cancer tumours with EGFR activating mutations.	Range Agreed	1	3	Date Agreed	30/11/2017	2	05/05/2017	2	Withdrawn by sponsor
10	15/EE/0448	189797	Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma. CheckMate 401: CHECKpoint pathway and nivolumab clinical Trial Evaluation 401.	Range Agreed	1	5	Date Agreed	30/06/2017	9	30/06/2017	9	Recruitment finished
11	15/LO/0545	172357	Clinical and device functional Assessment of Real world ICD pAtients - CARAT	Number Agreed	10	10	Date Agreed	31/10/2017	10	31/10/2017	10	Recruitment Finished

12	15/EE/0418	188945	CheckMate 451 – A randomised, multicentre, double-blind, Phase 3 study of Nivolumab, Nivolumab in combination with Ipilimumab, or placebo as maintenance therapy in subjects with extensive-stage disease small cell lung cancer (ED-SCLC) after completion of platinum-based first line chemotherapy	Range Agreed	2	4	Date Agreed	30/10/2019	3	08/09/2017	3	Recruitment finished
13	16/LO/0586	200579	An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment.	Number Agreed	3	3	Date Agreed	31/07/2017	10	24/02/2017	10	Recruitment Finished
14	15/LO/0834	172183	IMPassion 130 - A Phase III, multicentre, randomised, placebo-controlled study of MPDL3280A (Anti-PD-L1 antibody) in combination with nab-Paclitaxel compared with placebo with nab-Paclitaxel for patients with previously untreated metastatic triple-negative breast cancer.	Range Agreed	2	4	Date Agreed	31/07/2017	3	29/05/2017	3	Recruitment Finished
15	14/SC/1340	151325	A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5mg/day) as Treatment in Patients with Huntington's Disease.	Number Agreed	4	4	Date Agreed	31/12/2017	5	11/04/2017	5	Recruitment Finished
16	16/EE/0235	202344	A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment	Range Agreed	3	4	Date Agreed	31/10/2017	6	31/10/2017	6	Recruitment Finished

17	16/EE/0463	214371	COMPLEEMENT-1: An open-label, multicentre, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease	Number Agreed	4	4	Date Agreed	27/10/2017	4	16/10/2017	4	Recruitment Finished
18	17/EM/0014	219556	Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority Study Comparing Standard Wound Closure Technique with Drains (control) to Standard Wound Closure Techniques with TissuGlu® and No Drains (test) in Mastectomy.	Number Agreed	2	2	Date Agreed	29/09/2017	2	29/09/2017	5	Recruitment Finished
19	14/NW/1294	158613	A Phase III, multi-center, double-blind, placebo controlled, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease who are candidates for medical therapy.	Number Agreed	2	2	Date Agreed	17/04/2017	1	10/02/2017	1	Recruitment Finished
20	15/YH/0003	167451	ZINN - Randomized, Doubleblind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor	Range Agreed	3	12	Date Agreed	16/06/2017	1	21/04/2017	1	Withdrawn By Sponsor
21	15/LO/0337	171675	A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension	Range Agreed	2	3	Date Agreed	31/08/2017	0	31/08/2017	0	Recruitment Finished

22	15/LO/0443	172123	OPTIMISSM: Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.	Number Agreed	10	10	Date Agreed	28/02/2017	2	29/03/2017	2	Recruitment Finished
23	15/SC/0409	183061	Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration.	Range Agreed	5	10	Date Agreed	30/11/2017	2	07/04/2017	2	Recruitment Finished
24	14/WS/1146	166537	Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS), comparing rivaroxaban 15 mg once daily with aspirin 100 mg (NAVIGATE ESUS)	Number Agreed	20	20	Date Agreed	30/09/2017	12	20/09/2017	12	Recruitment finished
25	15/LO/1289	181953	An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures - CARD 3867 VOYAGER PAD	Range Agreed	20	40	Date Agreed	31/01/2018	6	30/09/2017	6	Recruitment Finished
26	15/NW/0592	185435	A randomised, double-blind, double-dummy, placebo-controlled, parallel-group multi-centre clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function.	Number Agreed	3	3	Date Agreed	11/08/2017	2	11/08/2017	2	Recruitment finished

27	16/LO/0351	190075	A double blind, randomized placebo controlled crossover multiple dose study of LJN452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhea (pBAD)	Number Agreed	5	5	Date Agreed	16/11/2017	3	16/11/2017	3	Recruitment Finished
28	16/LO/0448	198164	A Phase 2 study of LY2606368 in patients with extensive stage disease small cell lung cancer.	Number Agreed	1	1	Date Agreed	31/08/2017	0	17/01/2017	0	Recruitment Finished
29	16/EM/0320	208246	A Randomized, Multicentre, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in combination with Atezolizumab or Atezolizumab-Placebo in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer who have Received Prior Trastuzumab and Taxane Base Therapy [KATE-2]	Number Agreed	2	2	Date Agreed	04/07/2017	1	07/08/2017	1	Recruitment Finished
30	16/EM/0279	208089	PIONEER-5: Efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 diabetes and moderate renal impairment.	Number Agreed	5	5	Date Agreed	29/09/2017	3	29/09/2017	3	Recruitment finished
31	16/YH/0506	212039	A Randomized, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD	Number Agreed	2	2	Date Agreed	22/12/2017	1	22/12/2017	1	Recruitment Finished